



Clinical trial results:

A randomized, double-blind, placebo controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, dose relation, pharmacokinetics and pharmacodynamics of CJM112 in moderate to severe chronic hidradenitis suppurativa patients.

Summary

EudraCT number	2014-004731-39
Trial protocol	DE DK NL
Global end of trial date	23 November 2016

Results information

Result version number	v1
This version publication date	07 December 2017
First version publication date	07 December 2017

Trial information

Trial identification

Sponsor protocol code	CCJM112X2202
-----------------------	--------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02421172
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	CH-4002, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111,
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	23 November 2016
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	23 November 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To determine the efficacy of CJM112 High Dose in chronic hidradenitis suppurativa (HS) patients, by clinical responder rate at Week 16.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 April 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Denmark: 3
Country: Number of subjects enrolled	United States: 29
Country: Number of subjects enrolled	Germany: 9
Country: Number of subjects enrolled	Switzerland: 10
Country: Number of subjects enrolled	Netherlands: 15
Worldwide total number of subjects	66
EEA total number of subjects	27

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	65
From 65 to 84 years	1
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Study with 4 wks screening,two sequential treatment periods 16 wks (Period 1 & Extension Period 2)& 12 wks Follow-up. Randomization 2:1:1 to three sequences:Seq. 1: Period 1: CJM112 High Dose sc then Period 2: placebo sc; Seq. 2: Period 1: Placebo sc then Period 2: CJM112 Low Dose sc; Seq, 3: Period 1: Placebo sc then Period 2: CJM112 High Dose sc.

Pre-assignment

Screening details:

A total of 66 patients were enrolled, randomized and entered into two sequential periods (Period 1 and Extension Period 2) of which 60 patients completed Week 16 in Period 1 and entered Extension Period 2.

Period 1

Period 1 title	Period 1
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Period 1: CJM112 High Dose
------------------	----------------------------

Arm description:

Period 1: CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses

Arm type	Experimental
Investigational medicinal product name	CJM112
Investigational medicinal product code	CJM112
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses

Arm title	Period 1: Placebo
------------------	-------------------

Arm description:

Period 1: Placebo subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	CJM112
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses

Number of subjects in period 1	Period 1: CJM112 High Dose	Period 1: Placebo
Started	33	33
PD Analysis Set Period 1	31	33
Completed	29	31
Not completed	4	2
Adverse event, non-fatal	1	-
Patient/guardian decision	-	1
Lost to follow-up	3	1

Period 2

Period 2 title	Period 2
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor

Arms

Are arms mutually exclusive?	Yes
Arm title	Extension Period 2: CJM112 High Dose /Placebo

Arm description:

Extension Period 2: Placebo subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses this group. This group was on CJM112 High Dose in Period 1

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	CJM112
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses

Arm title	Extension Period 2: Placebo/CJM112 Low Dose
------------------	---

Arm description:

Extension Period 2: CJM112 Low Dose subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses this group. This group was on Placebo in Period 1

Arm type	Experimental
Investigational medicinal product name	CJM112
Investigational medicinal product code	CJM112
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

CJM112 Low Dose subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses

Arm title	Extension Period 2: Placebo/CJM112 High Dose
------------------	--

Arm description:

Extension Period 2: CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses this group. This group was on Placebo in Period 1

Arm type	Experimental
Investigational medicinal product name	CJM112
Investigational medicinal product code	CJM112
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses

Number of subjects in period 2	Extension Period 2: CJM112 High Dose /Placebo	Extension Period 2: Placebo/CJM112 Low Dose	Extension Period 2: Placebo/CJM112 High Dose
Started	29	16	15
Completed	22	13	14
Not completed	7	3	1
Adverse event, non-fatal	4	-	-
Patient/guardian decision	3	2	1
Lost to follow-up	-	1	-

Baseline characteristics

Reporting groups

Reporting group title	Period 1: CJM112 High Dose
Reporting group description:	
Period 1: CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses	
Reporting group title	Period 1: Placebo
Reporting group description:	
Period 1: Placebo subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses	

Reporting group values	Period 1: CJM112 High Dose	Period 1: Placebo	Total
Number of subjects	33	33	66
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	32	33	65
From 65-84 years	1	0	1
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	36	39	
standard deviation	± 9.8	± 10.9	-
Gender, Male/Female			
Units: Subjects			
Female	22	22	44
Male	11	11	22

End points

End points reporting groups

Reporting group title	Period 1: CJM112 High Dose
Reporting group description: Period 1: CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses	
Reporting group title	Period 1: Placebo
Reporting group description: Period 1: Placebo subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses	
Reporting group title	Extension Period 2: CJM112 High Dose /Placebo
Reporting group description: Extension Period 2: Placebo subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses this group. This group was on CJM112 High Dose in Period 1	
Reporting group title	Extension Period 2: Placebo/CJM112 Low Dose
Reporting group description: Extension Period 2: CJM112 Low Dose subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses this group. This group was on Placebo in Period 1	
Reporting group title	Extension Period 2: Placebo/CJM112 High Dose
Reporting group description: Extension Period 2: CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses this group. This group was on Placebo in Period 1	

Primary: Clinical responder rate at Period 1: Week 16

End point title	Clinical responder rate at Period 1: Week 16
End point description: Proportion of study participants achieving a clinical response in Hidradenitis Suppurativa - Physician Global Assessment (HS-PGA) score An HS-PGA responder in period 1 was a participant who had an initial HS-PGA score of at least 3 at baseline (Day 1, inclusion criterion) that decreased by at least 2 points.	
End point type	Primary
End point timeframe: Week 16	

End point values	Period 1: CJM112 High Dose	Period 1: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	31	32		
Units: participants	10	4		

Statistical analyses

Statistical analysis title	Clinical responder rate at Period 1: Week 16
Comparison groups	Period 1: Placebo v Period 1: CJM112 High Dose

Number of subjects included in analysis	63
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	posterior difference
Point estimate	0.194
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.004
upper limit	0.391

Secondary: Clinical responder rate Period 1 at Week 2, 4, 8 and 12

End point title	Clinical responder rate Period 1 at Week 2, 4, 8 and 12
End point description: Proportion of study participants achieving a clinical response in Hidradenitis Suppurativa - Physician Global Assessment (HS-PGA) score A HS-PGA responder in Period 1 is a study participant who had an initial HS-PGA score of at least 3 at Baseline (Day 1, inclusion criterion) that decreased by at least 2 points.	
End point type	Secondary
End point timeframe: Week 2, 4, 8 and 12	

End point values	Period 1: CJM112 High Dose	Period 1: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	31	32		
Units: participants				
Week 2	4	3		
Week 4	6	3		
Week 8	5	6		
Week 12	7	4		

Statistical analyses

No statistical analyses for this end point

Secondary: Pharmacokinetics (PK): Ctrough for CJM112 Period 1 and Period 2

End point title	Pharmacokinetics (PK): Ctrough for CJM112 Period 1 and Period 2 ^[1]
End point description: Ctrough is the serum concentration that is just prior to the beginning of, or at the end, of a dosing interval (mass/volume) for Period 1 (week 16) and Period 2/End of Study (week 44)	
End point type	Secondary
End point timeframe: Week 16 and Week 44	

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint analysis did not include placebo arms.

End point values	Period 1: CJM112 High Dose	Extension Period 2: Placebo/CJM11 2 Low Dose	Extension Period 2: Placebo/CJM11 2 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	28	13	14	
Units: ug/mL				
arithmetic mean (standard deviation)	21.4 (± 11.6)	3.1 (± 2.6)	24.4 (± 19.0)	

Statistical analyses

No statistical analyses for this end point

Secondary: Pharmacokinetic profile: T1/2 The terminal elimination half-life for Period 1 & Period 2/End of Study

End point title	Pharmacokinetic profile: T1/2 The terminal elimination half-life for Period 1 & Period 2/End of Study ^[2]
-----------------	--

End point description:

T1/2 The terminal elimination half-life for Period 1 (Week 16) and Period 2/End of Study (Week 44)

End point type	Secondary
----------------	-----------

End point timeframe:

Week 16, Week 44

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint analysis did not include placebo arms.

End point values	Period 1: CJM112 High Dose	Extension Period 2: Placebo/CJM11 2 Low Dose	Extension Period 2: Placebo/CJM11 2 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	26	1	7	
Units: days				
arithmetic mean (standard deviation)	16.09 (± 3.500)	22.81 (± 0)	19.85 (± 3.807)	

Statistical analyses

No statistical analyses for this end point

Secondary: Immunogenicity - Incidence of ADA-positive and ADA-negative in participants with or without pre-existing antibodies in Period 1 and Period 2/End of Study

End point title	Immunogenicity - Incidence of ADA-positive and ADA-negative in participants with or without pre-existing antibodies in Period
-----------------	---

End point description:

Immunogenicity - Incidence of semi-quantitative determination of anti-CJM112 antibodies or ADAs. ADA-positive and ADA-negative in participants with or without pre-existing antibodies Period 1 (week 16) and Period 2/End of Study (week 44)

End point type

Secondary

End point timeframe:

Baseline, End of Study (Week 44)

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint analysis did not include placebo arms.

End point values	Period 1: CJM112 High Dose	Extension Period 2: Placebo/CJM11 2 Low Dose	Extension Period 2: Placebo/CJM11 2 High Dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	33	16	15	
Units: participants				
Pre-existing Antibodies ADA negative	2	1	7	
Pre-existing Antibodies ADA positive	1	1	0	
NO Pre-existing Antibodies ADA negative	21	10	9	
NO Pre-existing Antibodies ADA positive	9	4	1	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	19.1

Reporting groups

Reporting group title	Period 1 CJM112 300 mg
Reporting group description:	Period 1 CJM112 300 mg
Reporting group title	Period 1 Placebo
Reporting group description:	Period 1 Placebo
Reporting group title	Extension Period 2 CJM112 300 mg/Placebo
Reporting group description:	Extension Period 2 CJM112 300 mg/Placebo
Reporting group title	Extension Period 2 Placebo/CJM112 50 mg
Reporting group description:	Extension Period 2 Placebo/CJM112 50 mg
Reporting group title	Extension Period 2 Placebo/CJM112 300 mg
Reporting group description:	Extension Period 2 Placebo/CJM112 300 mg

Serious adverse events	Period 1 CJM112 300 mg	Period 1 Placebo	Extension Period 2 CJM112 300 mg/Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 33 (0.00%)	1 / 33 (3.03%)	1 / 29 (3.45%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 33 (0.00%)	1 / 33 (3.03%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Groin abscess			

subjects affected / exposed	0 / 33 (0.00%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Extension Period 2 Placebo/CJM112 50 mg	Extension Period 2 Placebo/CJM112 300 mg	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 16 (0.00%)	0 / 15 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 16 (0.00%)	0 / 15 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Groin abscess			
subjects affected / exposed	0 / 16 (0.00%)	0 / 15 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Period 1 CJM112 300 mg	Period 1 Placebo	Extension Period 2 CJM112 300 mg/Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	25 / 33 (75.76%)	23 / 33 (69.70%)	20 / 29 (68.97%)
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	3 / 33 (9.09%)	1 / 33 (3.03%)	1 / 29 (3.45%)
occurrences (all)	3	1	1
Non-cardiac chest pain			
subjects affected / exposed	2 / 33 (6.06%)	1 / 33 (3.03%)	1 / 29 (3.45%)
occurrences (all)	2	1	2
Oedema peripheral			

subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
Pain subjects affected / exposed occurrences (all)	1 / 33 (3.03%) 1	2 / 33 (6.06%) 2	1 / 29 (3.45%) 1
Pyrexia subjects affected / exposed occurrences (all)	3 / 33 (9.09%) 4	1 / 33 (3.03%) 1	3 / 29 (10.34%) 5
Reproductive system and breast disorders Pruritus genital subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	1 / 33 (3.03%) 1	2 / 33 (6.06%) 2	2 / 29 (6.90%) 2
Oropharyngeal pain subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2	3 / 33 (9.09%) 3	0 / 29 (0.00%) 0
Rhinalgia subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
Investigations Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	1 / 33 (3.03%) 1	1 / 33 (3.03%) 1	1 / 29 (3.45%) 1
QRS axis abnormal subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
White blood cells urine subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
Injury, poisoning and procedural complications			

Contusion subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
Procedural pain subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 33 (0.00%) 0	1 / 29 (3.45%) 1
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 33 (0.00%) 0	2 / 29 (6.90%) 2
Headache subjects affected / exposed occurrences (all)	4 / 33 (12.12%) 5	3 / 33 (9.09%) 3	2 / 29 (6.90%) 3
Paraesthesia subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
Ear and labyrinth disorders			
Ear pain subjects affected / exposed occurrences (all)	1 / 33 (3.03%) 2	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
Sudden hearing loss subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
Tinnitus subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
Eye disorders			
Eye pruritus subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
Eyelid cyst subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2	0 / 33 (0.00%) 0	2 / 29 (6.90%) 2

Abdominal pain upper subjects affected / exposed occurrences (all)	1 / 33 (3.03%) 1	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2	5 / 33 (15.15%) 5	1 / 29 (3.45%) 1
Nausea subjects affected / exposed occurrences (all)	5 / 33 (15.15%) 6	3 / 33 (9.09%) 3	2 / 29 (6.90%) 3
Toothache subjects affected / exposed occurrences (all)	1 / 33 (3.03%) 1	3 / 33 (9.09%) 3	0 / 29 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	1 / 33 (3.03%) 1	1 / 33 (3.03%) 2	0 / 29 (0.00%) 0
Skin and subcutaneous tissue disorders			
Dry skin subjects affected / exposed occurrences (all)	1 / 33 (3.03%) 1	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
Dyshidrotic eczema subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 33 (0.00%) 0	0 / 29 (0.00%) 0
Hidradenitis subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	3 / 33 (9.09%) 3	0 / 29 (0.00%) 0
Intertrigo subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2	1 / 33 (3.03%) 1	0 / 29 (0.00%) 0
Pain of skin subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	1 / 33 (3.03%) 1	0 / 29 (0.00%) 0
Pruritus subjects affected / exposed occurrences (all)	3 / 33 (9.09%) 3	2 / 33 (6.06%) 2	2 / 29 (6.90%) 2
Rash			

subjects affected / exposed	0 / 33 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Skin exfoliation			
subjects affected / exposed	0 / 33 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 33 (0.00%)	1 / 33 (3.03%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 33 (0.00%)	2 / 33 (6.06%)	3 / 29 (10.34%)
occurrences (all)	0	2	4
Back pain			
subjects affected / exposed	5 / 33 (15.15%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	5	0	1
Myalgia			
subjects affected / exposed	0 / 33 (0.00%)	2 / 33 (6.06%)	1 / 29 (3.45%)
occurrences (all)	0	2	1
Tenosynovitis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Abscess			
subjects affected / exposed	0 / 33 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 33 (0.00%)	2 / 29 (6.90%)
occurrences (all)	0	0	2
Conjunctivitis			
subjects affected / exposed	2 / 33 (6.06%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	3	0	1
Cystitis			
subjects affected / exposed	3 / 33 (9.09%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	3	0	2
Eyelid infection			

subjects affected / exposed	0 / 33 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 33 (0.00%)	3 / 33 (9.09%)	0 / 29 (0.00%)
occurrences (all)	0	3	0
Influenza			
subjects affected / exposed	3 / 33 (9.09%)	1 / 33 (3.03%)	2 / 29 (6.90%)
occurrences (all)	3	1	3
Nasopharyngitis			
subjects affected / exposed	7 / 33 (21.21%)	4 / 33 (12.12%)	4 / 29 (13.79%)
occurrences (all)	9	4	4
Periorbital cellulitis			
subjects affected / exposed	0 / 33 (0.00%)	1 / 33 (3.03%)	0 / 29 (0.00%)
occurrences (all)	0	1	0
Skin infection			
subjects affected / exposed	0 / 33 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Tinea versicolour			
subjects affected / exposed	0 / 33 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	3 / 33 (9.09%)	0 / 33 (0.00%)	1 / 29 (3.45%)
occurrences (all)	3	0	1
Urinary tract infection			
subjects affected / exposed	2 / 33 (6.06%)	2 / 33 (6.06%)	1 / 29 (3.45%)
occurrences (all)	2	2	1
Metabolism and nutrition disorders			
Diabetes mellitus			
subjects affected / exposed	0 / 33 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 33 (0.00%)	0 / 33 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Extension Period 2 Placebo/CJM112 50 mg	Extension Period 2 Placebo/CJM112 300 mg	
Total subjects affected by non-serious adverse events subjects affected / exposed	13 / 16 (81.25%)	14 / 15 (93.33%)	
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 16 (0.00%)	1 / 15 (6.67%)	
occurrences (all)	0	1	
Non-cardiac chest pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 15 (0.00%)	
occurrences (all)	0	0	
Oedema peripheral			
subjects affected / exposed	0 / 16 (0.00%)	1 / 15 (6.67%)	
occurrences (all)	0	1	
Pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 15 (0.00%)	
occurrences (all)	0	0	
Pyrexia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 15 (0.00%)	
occurrences (all)	0	0	
Reproductive system and breast disorders			
Pruritus genital			
subjects affected / exposed	0 / 16 (0.00%)	1 / 15 (6.67%)	
occurrences (all)	0	1	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 16 (0.00%)	0 / 15 (0.00%)	
occurrences (all)	0	0	
Oropharyngeal pain			
subjects affected / exposed	1 / 16 (6.25%)	0 / 15 (0.00%)	
occurrences (all)	1	0	
Rhinalgia			
subjects affected / exposed	1 / 16 (6.25%)	0 / 15 (0.00%)	
occurrences (all)	1	0	
Investigations			

Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 15 (0.00%) 0	
QRS axis abnormal subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 15 (0.00%) 0	
White blood cells urine subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 15 (6.67%) 1	
Injury, poisoning and procedural complications Contusion subjects affected / exposed occurrences (all) Procedural pain subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0 1 / 16 (6.25%) 1	1 / 15 (6.67%) 1 1 / 15 (6.67%) 1	
Nervous system disorders Dizziness subjects affected / exposed occurrences (all) Headache subjects affected / exposed occurrences (all) Paraesthesia subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0 3 / 16 (18.75%) 5 1 / 16 (6.25%) 1	0 / 15 (0.00%) 0 0 / 15 (0.00%) 0 0 / 15 (0.00%) 0	
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all) Sudden hearing loss subjects affected / exposed occurrences (all) Tinnitus subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0 1 / 16 (6.25%) 1 1 / 16 (6.25%) 1	1 / 15 (6.67%) 1 0 / 15 (0.00%) 0 0 / 15 (0.00%) 0	

Eye disorders			
Eye pruritus			
subjects affected / exposed	1 / 16 (6.25%)	0 / 15 (0.00%)	
occurrences (all)	1	0	
Eyelid cyst			
subjects affected / exposed	1 / 16 (6.25%)	0 / 15 (0.00%)	
occurrences (all)	2	0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 15 (0.00%)	
occurrences (all)	0	0	
Abdominal pain upper			
subjects affected / exposed	0 / 16 (0.00%)	1 / 15 (6.67%)	
occurrences (all)	0	1	
Diarrhoea			
subjects affected / exposed	0 / 16 (0.00%)	2 / 15 (13.33%)	
occurrences (all)	0	2	
Nausea			
subjects affected / exposed	1 / 16 (6.25%)	0 / 15 (0.00%)	
occurrences (all)	1	0	
Toothache			
subjects affected / exposed	2 / 16 (12.50%)	0 / 15 (0.00%)	
occurrences (all)	2	0	
Vomiting			
subjects affected / exposed	2 / 16 (12.50%)	0 / 15 (0.00%)	
occurrences (all)	2	0	
Skin and subcutaneous tissue disorders			
Dry skin			
subjects affected / exposed	1 / 16 (6.25%)	1 / 15 (6.67%)	
occurrences (all)	2	1	
Dyshidrotic eczema			
subjects affected / exposed	0 / 16 (0.00%)	1 / 15 (6.67%)	
occurrences (all)	0	1	
Hidradenitis			
subjects affected / exposed	0 / 16 (0.00%)	2 / 15 (13.33%)	
occurrences (all)	0	2	
Intertrigo			

subjects affected / exposed	0 / 16 (0.00%)	1 / 15 (6.67%)	
occurrences (all)	0	1	
Pain of skin			
subjects affected / exposed	1 / 16 (6.25%)	0 / 15 (0.00%)	
occurrences (all)	1	0	
Pruritus			
subjects affected / exposed	0 / 16 (0.00%)	0 / 15 (0.00%)	
occurrences (all)	0	0	
Rash			
subjects affected / exposed	0 / 16 (0.00%)	1 / 15 (6.67%)	
occurrences (all)	0	1	
Skin exfoliation			
subjects affected / exposed	1 / 16 (6.25%)	0 / 15 (0.00%)	
occurrences (all)	2	0	
Urticaria			
subjects affected / exposed	1 / 16 (6.25%)	0 / 15 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 16 (0.00%)	1 / 15 (6.67%)	
occurrences (all)	0	1	
Back pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 15 (0.00%)	
occurrences (all)	0	0	
Myalgia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 15 (0.00%)	
occurrences (all)	0	0	
Tenosynovitis			
subjects affected / exposed	1 / 16 (6.25%)	0 / 15 (0.00%)	
occurrences (all)	1	0	
Infections and infestations			
Abscess			
subjects affected / exposed	1 / 16 (6.25%)	0 / 15 (0.00%)	
occurrences (all)	1	0	
Bronchitis			

subjects affected / exposed	1 / 16 (6.25%)	0 / 15 (0.00%)	
occurrences (all)	1	0	
Conjunctivitis			
subjects affected / exposed	0 / 16 (0.00%)	1 / 15 (6.67%)	
occurrences (all)	0	1	
Cystitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 15 (0.00%)	
occurrences (all)	0	0	
Eyelid infection			
subjects affected / exposed	0 / 16 (0.00%)	1 / 15 (6.67%)	
occurrences (all)	0	1	
Gastroenteritis			
subjects affected / exposed	1 / 16 (6.25%)	0 / 15 (0.00%)	
occurrences (all)	1	0	
Influenza			
subjects affected / exposed	0 / 16 (0.00%)	1 / 15 (6.67%)	
occurrences (all)	0	1	
Nasopharyngitis			
subjects affected / exposed	2 / 16 (12.50%)	3 / 15 (20.00%)	
occurrences (all)	2	3	
Periorbital cellulitis			
subjects affected / exposed	1 / 16 (6.25%)	0 / 15 (0.00%)	
occurrences (all)	1	0	
Skin infection			
subjects affected / exposed	0 / 16 (0.00%)	1 / 15 (6.67%)	
occurrences (all)	0	1	
Tinea versicolour			
subjects affected / exposed	1 / 16 (6.25%)	0 / 15 (0.00%)	
occurrences (all)	1	0	
Upper respiratory tract infection			
subjects affected / exposed	2 / 16 (12.50%)	0 / 15 (0.00%)	
occurrences (all)	2	0	
Urinary tract infection			
subjects affected / exposed	3 / 16 (18.75%)	0 / 15 (0.00%)	
occurrences (all)	3	0	
Metabolism and nutrition disorders			

Diabetes mellitus			
subjects affected / exposed	0 / 16 (0.00%)	1 / 15 (6.67%)	
occurrences (all)	0	1	
Hypomagnesaemia			
subjects affected / exposed	1 / 16 (6.25%)	0 / 15 (0.00%)	
occurrences (all)	1	0	
Vitamin D deficiency			
subjects affected / exposed	0 / 16 (0.00%)	1 / 15 (6.67%)	
occurrences (all)	0	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 September 2015	Amendment 1: The purpose of this amendment was to implement the request of Ethics Committee in Germany (Berlin) to allow screening for pre-existing HBV infections. Additional serological assessment was added to monitor for (chronic) HBV infection prior to the first application of the study drug. Screening for antibodies against HB core antigen (anti-HBc) – additional to HB surface antigen testing (HBsAg) was made mandatory and patients with a positive test result in either test were to be excluded from the study. In addition, the number of incisions was limited to one incision per period as this might influence primary endpoint of the study. Further, minor changes were made to inclusion-exclusion criteria to clarify at which point inclusion/exclusion criterion should be confirmed. Other minor modifications were made to improve readability or clarity.
10 October 2016	Amendment 2: The purpose of this amendment was to move evaluation of serum total IL-17A/F (heterodimer) from secondary to exploratory objectives. The total IL-17A/F assay in serum was validated according to most recent international guidelines and quality standards/SOPs defined by Novartis Pharma AG based on good laboratory practices. The selected immunoassay platform (Erenna from Singulex) was not GxP-validated. Thus, total IL-17A/F data were exploratory in nature. Therefore, the evaluation of total IL-17A/F in serum was moved from secondary to exploratory objectives.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported